Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
2 Biotech Stocks to Buy and Hold for 10 Years
01:05pm, Saturday, 30'th Apr 2022 The Motley Fool
These two companies have moved in opposite directions on the stock market so far this year, but now seem set to move up and to the right.
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
02:09pm, Thursday, 28'th Apr 2022 Benzinga
Upgrades
According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago
What 4 Analyst Ratings Have To Say About CRISPR Therapeutics
01:14pm, Thursday, 28'th Apr 2022 Benzinga
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
3
0
0
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
01:18pm, Wednesday, 27'th Apr 2022 The Motley Fool
Make sure that you're aware of the risks before buying these promising growth stocks.
Crispr Therapeutics: Progress, Risk, And Reward
10:18am, Wednesday, 27'th Apr 2022
CRISPR Therapeutics continues to make progress in all of its development platforms. The company continues to confirm the filing date for CTX001.
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
09:18am, Wednesday, 27'th Apr 2022
Make sure that you're aware of the risks before buying these promising growth stocks.
3 Cathie Wood Stocks to Count on in Q2
06:45am, Tuesday, 26'th Apr 2022
These Cathie Wood Stocks have their risks but offer a massive upside potential ahead The post 3 Cathie Wood Stocks to Count on in Q2 appeared first on InvestorPlace. More From InvestorPlace Stock Prod
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
10:00pm, Friday, 22'nd Apr 2022 Zacks Investment Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.68, marking a +0.27% move from the previous day.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
06:58pm, Friday, 22'nd Apr 2022 Zacks Investment Research
On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.
7 Potential Biotech Stocks Buyout Targets in 2022
08:10am, Thursday, 21'st Apr 2022
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl
3 Ominous Reasons to Avoid This Biotech Pioneer
10:20am, Tuesday, 19'th Apr 2022 The Motley Fool
They point to trouble for investors counting on a rebound.
3 Ominous Reasons to Avoid This Biotech Pioneer
06:20am, Tuesday, 19'th Apr 2022
They point to trouble for investors counting on a rebound.
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
02:03pm, Thursday, 14'th Apr 2022 Zacks Investment Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates fo
Is Now the Time to Bet on This Game-Changing Stock?
12:00pm, Thursday, 14'th Apr 2022 The Motley Fool
This company's targeting a market with explosive growth.
CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030
02:45pm, Wednesday, 13'th Apr 2022 The Motley Fool
The only thing standing in the way is the clinical trials process, which takes time and patience.
